Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Diabetes Mellitus
Interventions
DRUG

Acarbose

After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.

Trial Locations (1)

Unknown

Taichung Veterans General Hospital, Taichung

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Changhua Christian Hospital

OTHER

lead

Taichung Veterans General Hospital

OTHER

NCT00417729 - Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM | Biotech Hunter | Biotech Hunter